Pulse Biosciences raised $20 million in an initial public offering this week after floating 5 million shares at $4 apiece, for a fully diluted valuation of $51 million. Burlingame, Calif.-based Pulse is developing “nano-pulse electro-signaling,” in which extremely short-duration pulsed electrical fields are directed at solid tumors. It’s designed to induce a type of programmed cell death […]
Pulse Biosciences
Pulse Biosciences registers for $20m IPO
Pulse Biosciences, which is developing pulsed electric field technology to treat solid tumors, last week filed for an initial public offering worth $20 million. Burlingame, Calif.-based Pulse said it plans to float 5 million shares at $4 apiece, for a fully diluted valuation of $51 million. The company is developing “nano-pulse electro-signaling,” in which extremely […]